Ubiquitin-Specific Protease 18 in Chronic Kidney Disease-Another Emerging Biomarker to Consider?

• Published in: Biomedicines Vol. 12; no. 5; p. 1073
• Main Authors: Dziamałek-Macioszczyk, Paulina, Winiarska, Agata, Pawłowska, Anna, Macioszczyk, Jan, Wojtacha, Paweł, Stompór, Tomasz
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01-05-2024
• Subjects: Biomarkers; Biopsy; Blood pressure; Cardiac muscle; cardiac remodeling; Cardiomyocytes; Cardiovascular diseases; Cell cycle; Cell division; Cell signaling; chronic heart failure; Chronic illnesses; chronic kidney disease; Chronic kidney failure; Creatinine; deubiquitinase; Diabetes; Glomerulonephritis; Heart failure; Hemodialysis; Hypertension; Ischemia; Kidney diseases; Kidney transplantation; Kidney transplants; Kinases; Mycophenolate sodium; Organ transplant recipients; Pathophysiology; Patients; Proteases; Proteins; proteinuria; Renal replacement therapy; Steroids; Transplantation of organs, tissues, etc; Tumor necrosis factor-TNF; Ubiquitin; ubiquitin-specific protease 18; Ubiquitin-specific proteinase; Urine; USP18 protein; Viral infections; Poland; albuminuria; chronic kidney disease; proteinuria; ubiquitin-specific protease 18; cardiac remodeling; chronic heart failure; deubiquitinase
• DOI: 10.3390/biomedicines12051073
• EISSN: 2227-9059

Ubiquitin-specific protease 18 (USP18) is a protein recognized for its dual enzymatic and non-enzymatic nature. It is involved in many physiological processes like the cell cycle and cell signaling. It also suppresses heart muscle remodeling upon an increase in the afterload. The role of USP18 in kidney pathology remains unknown. The objective of the study was to assess the relationship between serum and urine USP18 levels, the factors contributing to cardiovascular risk, and the markers of kidney disease activity at different stages of chronic kidney disease (CKD). One hundred participants, aged between 24 and 85 years (mean 53.1 ± 17.1 years), were included. Five groups (n = 20 each) were recruited according to their renal status (healthy individuals, patients with proteinuric glomerulonephritis, patients with non-proteinuric CKD, patients who were treated with hemodialysis, and kidney transplant recipients). The measurements of serum and urine USP18 levels were performed using ELISA. The median serum USP18 level was the highest in healthy participants (1143.0 pg/mL) and kidney transplant recipients (856.6 pg/mL), whereas, in individuals with different forms of CKD, it fitted within the range of 402.1-471.9 pg/mL. Urinary USP18 reached the highest level in the group of CKD patients not yet on dialysis (303.3 pg/mL). Only in this group did it correlate with serum creatinine and urea concentrations. Our results suggest the inhibition of cardioprotective USP18 signaling when kidney function is impaired. Moreover, an increased level of urinary USP18 may indicate chronic tubular damage.